Does Wegovy Cause Migraines or Headaches? FDA Label & Trial Evidence Review

“Does Wegovy cause migraines or headaches?” is one of the most-searched practical questions on semaglutide 2.4 mg. The honest read of the evidence is two-part: headache is real and on the FDA label^[5]; migraine specifically is not. This article walks through the Wegovy Section 6.1 headache rate, the STEP-1^[1] and STEP-2^[2] trial pictures, the SELECT^[3] long-duration cardiovascular outcome trial AE profile, what the 2025 FAERS pharmacovigilance analysis^[4] actually found on migraine (and what it does not), the four candidate mechanisms (dehydration, low blood sugar, caffeine withdrawal, hormonal shifts from rapid weight loss), the red flags that warrant urgent contact with the prescriber, the comparison to Ozempic / Mounjaro / Zepbound, and the practical relief protocol.

At a glance

• Wegovy §6.1 headache rate: 14% vs 10% placebo — verbatim from FDA label Table 3, “Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction”^[5].
• Migraine specifically: not listed as a Wegovy adverse reaction on the DailyMed label^[5]. The 2025 FAERS pharmacovigilance analysis^[4] reports a class-level migraine reporting-odds-ratio of 1.28 (95% CI 1.06–1.55) — a disproportionality signal, not a causal finding.
• Drug-attributable share: ~4 percentage points above placebo. Headache is not the dominant Wegovy safety signal — the GI cluster (nausea, diarrhea, vomiting, constipation) is.
• Most likely mechanism: dehydration plus blunted thirst, compounded by GI-symptom fluid losses during titration. Hypoglycemia is rare in obesity-indication patients without T2D.
• Highest-risk window: the first 4–8 weeks of treatment and the 1–2 weeks after each dose escalation step.
• First-line OTC: acetaminophen, not ibuprofen. The Wegovy label^[5] warns of postmarketing acute kidney injury cases following dehydration from GI side effects; NSAIDs compound that risk.
• Red flags include: sudden thunderclap headache, headache with new vision changes (rule out IIH), neurologic symptoms, fever with stiff neck, or persistence beyond 4 weeks at a stable dose.

What the Wegovy FDA label §6.1 actually says about headache

The Wegovy DailyMed label^[5] Section 6.1 reports a pooled adverse-reactions table from the STEP-1, STEP-2, STEP-3, and STEP-5 trials. Table 3 is titled “Adverse Reactions (≥2% and Greater Than Placebo) in WEGOVY 2.4 mg Injection-treated Adults with Obesity or Overweight for Weight Reduction.” The headache row in that table reads:

• WEGOVY (semaglutide 2.4 mg once weekly): 14%
• Placebo: 10%

The drug-attributable share is roughly 4 percentage points above the placebo background rate. The placebo rate of 10% is itself substantial — headache is common in any adult population followed for many months in a clinical trial, and many headaches on Wegovy would have happened with or without the drug. The label does not list migraine as a separate adverse reaction. The label also notes that headache ascertainment was patient-reported during scheduled study visits; the actual experienced frequency in routine clinical practice may differ.

What STEP-1, STEP-2, and SELECT measured

STEP-1^[1] was the pivotal 68-week placebo-controlled Phase 3 trial that supported the FDA approval of Wegovy for chronic weight management. It randomized 1,961 adults with overweight or obesity (without T2D) to weekly semaglutide 2.4 mg or placebo. The AE table reported headache as a common adverse reaction in the semaglutide arm, consistent with the label-pooled 14% vs 10% figure.

STEP-2^[2] ran for 68 weeks in 1,210 adults with overweight or obesity and type 2 diabetes, randomizing to semaglutide 2.4 mg, semaglutide 1.0 mg (the Ozempic T2D dose), or placebo. The AE profile in the 2.4 mg arm included headache at rates consistent with STEP-1.

SELECT^[3] is the load-bearing long-duration AE picture: 17,604 adults with obesity and pre-existing cardiovascular disease (without T2D) randomized to semaglutide 2.4 mg or placebo, mean follow-up 39.8 months. Over nearly four years on treatment, the AE profile remained consistent with the STEP-program shorter-duration trials. Headache did not emerge as a late-onset or progressive signal — the pattern is titration-phase weighted, not chronic-treatment weighted.

Two implications follow. First, the Wegovy headache signal is modest, drug-attributable rate is ~4 percentage points, and the dominant safety picture is GI (nausea, diarrhea, vomiting, constipation). Second, the headache is concentrated in the first 4–8 weeks of treatment and the 1–2 weeks after each dose escalation step — the same windows in which the GI cluster peaks, which is the strongest clue to the mechanism.

Migraine specifically: what the evidence does and does not show

The Wegovy DailyMed label^[5] does not list migraine as an adverse reaction in Section 6 (adverse reactions). The STEP-1^[1], STEP-2^[2], and SELECT^[3] publications report headache as the common AE but do not separately tabulate migraine. There is no Wegovy-attributed migraine rate in the published pivotal trial program.

The only published migraine-specific signal comes from a 2025 FAERS pharmacovigilance analysis^[4] of neuropsychiatric adverse events on GLP-1 receptor agonists as a class. That study reports a reporting-odds-ratio (ROR) for migraine of 1.28 (95% CI 1.06–1.55) — flagged as the first detected migraine signal for the class. The same analysis reports an ROR for headache of 1.74 (95% CI 1.65–1.84). Median time from drug initiation to symptom onset across the neuropsychiatric AE set was 16 days.

Three important caveats apply to the FAERS signal:

1. FAERS is a spontaneous reporting database. Reporting ratios are not incidence rates and not causal findings. They are hypothesis-generating signals subject to reporting bias, channeling bias, and confounding by indication.
2. The signal is class-level, not Wegovy-specific. The analysis covered the GLP-1 receptor agonist class as a whole — semaglutide, liraglutide, dulaglutide, tirzepatide, etc. — not Wegovy in isolation.
3. Obesity itself is a migraine risk factor. A patient population enriched for obesity at baseline will have a higher background migraine prevalence than the general population. Whether the reported signal reflects drug effect, weight-loss trajectory, or the underlying population is not separable from the FAERS data alone.

The honest framing for a patient asking “does Wegovy cause migraines?”: there is a class-level pharmacovigilance signal worth taking seriously, but no Wegovy-attributed migraine rate has been established in the pivotal trial program, and migraine is not on the FDA label. Patients with a pre-existing migraine history should disclose it to the prescriber, monitor symptom patterns during titration, and seek evaluation if migraine frequency or severity changes meaningfully.

Mechanism: why Wegovy can produce a headache

The published literature does not establish a single drug-receptor pathway for semaglutide-related headache. The candidate drivers map onto a multifactorial picture concentrated in the titration phase.

1. Dehydration from blunted thirst plus GI losses (the dominant driver)

Semaglutide reduces spontaneous food intake and, by overlapping hypothalamic GLP-1 receptor circuits, blunts spontaneous thirst. Nausea, vomiting, and diarrhea (the dominant Wegovy GI cluster reported in STEP-1^[1]) compound the hydration deficit by reducing intake and increasing output. The result is mild chronic underhydration, a classical headache trigger. The Wegovy label^[5] specifically flags postmarketing acute kidney injury cases following dehydration from GI side effects — the hydration target is a safety priority beyond headache relief.

2. Low blood sugar (uncommon in obesity-indication patients without T2D)

Semaglutide is a glucose-dependent insulin secretagogue. Hypoglycemia is rare in Wegovy patients without T2D — the obesity indication enrolls patients with normal or impaired glucose tolerance, not patients on insulin or a sulfonylurea. In STEP-1^[1] hypoglycemia rates were comparable between the semaglutide and placebo arms. The clinically important exception is the STEP-2^[2] population (overweight or obesity + T2D), where patients on background insulin or sulfonylurea face elevated hypoglycemia risk and the Wegovy label^[5] specifies that the concomitant insulin or sulfonylurea dose should be reduced. For these patients, a headache with shakiness, sweating, palpitations, irritability, or confusion is a glucose check first.

3. Caffeine withdrawal during appetite suppression

Many Wegovy patients drink substantially less coffee in the first few weeks of titration — nausea, early satiety, and the “food noise” reduction all suppress habitual coffee intake. Patients drinking 3–4 cups per day who drop to 1 cup or zero can experience classic caffeine-withdrawal headache (peak 24–48 hours after the last dose, lasting 2–9 days). This is not a drug effect per se — it is a behavioral consequence of appetite suppression — but it is a real and common contributor to titration-phase headache and is easily missed because the pattern is obvious only in retrospect. Patients who notice headache that fits the caffeine-withdrawal pattern can taper rather than cold-turkey the coffee.

4. Hormonal shifts from rapid weight loss

Rapid weight loss is associated with shifts in estrogen, progesterone, cortisol, and thyroid hormone profiles. In patients with a pre-existing migraine history — particularly menstrual-cycle-linked migraine in premenopausal patients — hormonal flux is a known trigger, and the rapid weight-loss trajectory on Wegovy may change the symptom pattern. This is also the most plausible biological pathway for the class-level FAERS migraine signal^[4]: weight-loss-driven hormonal shifts plausibly unmask or modulate underlying migraine in a subset of susceptible patients. The clinical pattern, however, has not been formally characterized in the pivotal trial program.

A fifth candidate driver — blood pressure shifts in patients on antihypertensives, where rapid weight loss makes the antihypertensive dose relatively over-aggressive — is plausible but most relevant to the SELECT^[3] cardiovascular-disease population. Home BP monitoring gives the prescriber the data to adjust safely. Patients should not self-adjust antihypertensive medications.

How Wegovy headache compares to Ozempic, Mounjaro, and Zepbound

At the maximum dose for each indication, the trial-reported headache rates cluster in a narrow band:

Two takeaways. First, Wegovy is roughly 1 percentage point higher than tirzepatide 15 mg at maximum dose on headache — a real but small difference that requires cross-trial caution. Second, the placebo background rate (9–10% across both pivotal obesity trials) is itself substantial, which is the strongest reminder that “14% on Wegovy” is not the same as “Wegovy causes a headache in 14% of patients” — the drug-attributable share is ~4 percentage points.

For Ozempic (semaglutide 1 mg, T2D indication), the headache rate in published trials is lower than Wegovy — the 2.4 mg dose used in Wegovy is more than double the maintenance T2D dose of Ozempic, and the AE intensity scales with dose. Patients switching from Ozempic 1 mg to Wegovy 2.4 mg commonly experience renewed titration-phase symptoms, including headache.

The same-molecule companions are:

• Same molecule, T2D indication: Does Mounjaro cause headaches? Frequency, mechanism & relief evidence review — the SURPASS T2D companion. Hypoglycemia is the load-bearing differential.
• Different molecule, obesity indication: Does Zepbound cause headaches? Frequency, mechanism & relief evidence review — the SURMOUNT-1 / SURMOUNT-4 / SURMOUNT-OSA picture.

Practical relief protocol for Wegovy headache

1. Active hydration, not thirst-driven. Target 64–80 oz (2–2.5 L) of fluid per day, tracked rather than estimated. Set timed reminders if necessary. The Wegovy label^[5] warns about dehydration driving acute kidney injury — the hydration target is a safety priority beyond headache.
2. Electrolytes during active GI symptoms. Oral rehydration salts (the WHO formulation or low-sugar commercial options like LMNT) are preferable to plain water when a patient is actively losing fluid through vomiting or diarrhea. Be cautious with sugar-loaded sports drinks if there is a T2D or pre-diabetes component.
3. Audit caffeine intake. Patients who have dropped from 3–4 cups per day to 1 cup or zero in the first 2 weeks of titration should consider a deliberate taper rather than continuing the cold-turkey pattern. Caffeine-withdrawal headache peaks 24–48 hours after the last dose and lasts 2–9 days.
4. Acetaminophen, not ibuprofen, as first-line OTC. Acetaminophen (Tylenol, paracetamol) is not specifically flagged on the Wegovy label as a concern. Ibuprofen and other NSAIDs compound the renal-perfusion risk that dehydration already creates — the Wegovy label^[5] warns of postmarketing acute kidney injury cases following dehydration from GI side effects. Patients with liver conditions or on other hepatotoxic medications should confirm acetaminophen dosing with a prescriber or pharmacist.
5. Stay at the current dose if headache emerges mid-titration. The Wegovy label permits flexible titration. The standard prescriber response to a difficult titration step is to stay at the current dose for an additional 4 weeks rather than escalate on schedule. Pushing through escalation with an active headache often extends the symptom window.
6. For pre-existing migraine: track patterns. Patients with a baseline migraine history should keep a symptom log through the first 8–12 weeks of treatment — trigger, time-of-day, dose-step proximity, hormonal phase, hydration status. If migraine frequency or severity changes meaningfully, that is information for the prescriber, not a self-managed event.

Red flags — when a Wegovy headache is not just titration

Most Wegovy headaches are mild, mechanistically benign, and resolve with the steps above. A small share are warning signs of something serious. The clinical pattern below should prompt immediate evaluation regardless of medication status.

The IIH question

Idiopathic intracranial hypertension (IIH) — previously called pseudotumor cerebri — is a syndrome of elevated intracranial pressure without a structural cause, classically presenting with headache and vision changes. Case reports in the published literature have described IIH in patients on GLP-1 receptor agonists, but the data is at the case-report level. IIH is also strongly associated with obesity itself and with rapid weight changes in either direction — making the causal attribution to the drug versus to the weight trajectory difficult. The Wegovy DailyMed label^[5] does not list IIH in Section 6 (adverse reactions) as of the current revision.

The pragmatic implication is not that Wegovy causes IIH at any meaningful rate — that has not been established. The implication is that a Wegovy patient who develops headache plus visual symptoms should be evaluated for IIH the same as any other patient with that presentation, because IIH is treatable and progressive visual loss is the worst-case outcome of an untreated case. Headache plus new vision changes is the trigger to call the prescriber the same day.

Bottom line for the “Wegovy migraine and headache” question

1. Headache is on the label. Wegovy §6.1^[5] reports 14% on semaglutide 2.4 mg vs 10% on placebo, a drug-attributable rate of ~4 percentage points. Not the dominant safety signal — the GI cluster is.
2. Migraine is not on the label. The Wegovy DailyMed label^[5] does not list migraine as an adverse reaction. The only published signal is a 2025 class-level FAERS pharmacovigilance ROR of 1.28^[4] — hypothesis-generating, not causal, not Wegovy-specific.
3. Dehydration is the load-bearing mechanism in obesity-indication patients without T2D. Active hydration, low-sugar electrolytes during GI symptoms, and a caffeine audit cover most cases.
4. Hypoglycemia matters only in STEP-2-style patients (T2D + obesity, on background insulin or sulfonylurea). Glucose check first in that population.
5. First-line OTC is acetaminophen. Ibuprofen and other NSAIDs compound the dehydration plus renal risk that the Wegovy label flags.
6. Pre-existing migraine: track patterns through titration. Hormonal shifts from rapid weight loss are the most plausible biological pathway for migraine modulation, but the clinical pattern has not been formally characterized.
7. Red flags are urgent. Thunderclap headache, headache with vision changes (rule out IIH), neurologic symptoms, severe abdominal pain (rule out pancreatitis / gallbladder), fever with stiff neck, or persistence >4 weeks at a stable dose all warrant prescriber contact or emergency evaluation.

For the broader Wegovy clinical picture, the Wegovy drug page consolidates pricing, dose tiers, FDA-approved indications, and provider availability. For the full GLP-1 side-effect cross-trial picture, see our GLP-1 side-effects evidence review covering the full STEP / SURPASS / SURMOUNT picture, and the GLP-1 side-effect Q&A hub for the patient-facing question list.